Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05949021 | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Mridula George, MDOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT00572481 | Axillary Reverse Mapping(ARM) | active not recruiting | Phase 2 | 1,000 | University of ArkansasOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03707340 | A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04821141 | Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | active not recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04009044 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | active not recruiting | Phase 2 | 156 | Northwestern UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT01203839 | Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer | active not recruiting | Phase 2 | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02562118 | Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04520269 | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | active not recruiting | Phase 1 / Phase 2 | 74 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04280536 | Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) | active not recruiting | Phase 1 / Phase 2 | 86 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03820063 | Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study(TRAIN-3) | active not recruiting | Phase 2 | 462 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer(PELICAN) | active not recruiting | Phase 2 | 52 | Institut Paoli-CalmettesOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04759248 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer(ATREZZO) | active not recruiting | Phase 2 | 55 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06599216 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer | active not recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06198751 | A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | active not recruiting | Phase 2 | 104 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06224244 | External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients(ESIBIRE) | active not recruiting | Phase 2 | 180 | Regina Elena Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02436993 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | active not recruiting | Phase 2 | 120 | University of California, IrvineOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 13 | University of Illinois at ChicagoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03831178 | Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting(DHA-WIN) | active not recruiting | Phase 2 | 76 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06394661 | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | active not recruiting | Phase 2 | 109 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 23, 2025 | clinicaltrials |
| NCT02788981 | Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 29 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02546232 | Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting | active not recruiting | Phase 2 | 196 | Oslo University HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05463601 | Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | active not recruiting | Phase 2 | 132 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03161353 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.(PHERGain) | active not recruiting | Phase 2 | 377 | MedSIROTHER | 7 | Apr 23, 2025 | clinicaltrials |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | active not recruiting | Phase 2 | 25 | Mridula George, MDOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib(DIANER) | active not recruiting | Phase 2 | 177 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy(HELEX) | active not recruiting | Phase 2 | 128 | Baylor Breast Care CenterOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02547987 | Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer(CADENCE) | active not recruiting | Phase 2 | 25 | Mothaffar RimawiOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03324425 | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer(SIMPHONY) | active not recruiting | Phase 2 | 5 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03944434 | FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer(FACILE) | active not recruiting | Phase 2 | 116 | Fondazione Sandro PitiglianiOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT00248287 | PhII ICb With/Without Erbitux in MBC Pts(CA225200) | active not recruiting | Phase 2 | 154 | US Oncology ResearchINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02752685 | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | active not recruiting | Phase 2 | 70 | NYU Langone HealthOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02299999 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer(SAFIR02_Breast) | active not recruiting | Phase 2 | 1,460 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03875573 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:(Neo-CheckRay) | active not recruiting | Phase 2 | 147 | Jules Bordet InstituteOTHER | 2 | Dec 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2025source: clinicaltrials